REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Abroad (travel likely)Recruiting

Conditions

Ovarian Cancer · Advanced Ovarian Carcinoma · Fallopian Tube Carcinoma · Primary Peritoneal Cancer · PARP Inhibitor · Fatigue Related to Cancer Treatment · Fatigue in Cancer Survivors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Colorado Cancer Center-Anschutz, Aurora, Colorado, United States
Contact: Study coordinator (Evamaria Bravo, MS) · evamaria.kentbravo@cuanschutz.edu · 303-724-0131
Contact: Principal Investigator (Carolyn Lefkowits, MD, MPH, MS)
University of Colorado Boulder, Boulder, Colorado, United States
Contact: Study coordinator (Madeline Nealis, MPH) · revitalize@colorado.edu · 720-515-9461
Contact: Study coordinator (Sarah Genung, BA MSc) · revitalize@colorado.edu · 720-515-9461
Contact: Principal Investigator (Joanna J Arch, PhD)
Massachusetts General Hospital-Cancer Center, Boston, Massachusetts, United States
Contact: Study coordinator (Richard Penson, MBBS) · rpenson@mgb.org · 617-724-4800
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Contact: Study coordinator (Page Widick, MD) · pwidick@bidmc.harvard.edu · 617-667-2100
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Alexi Wright, MD, MPH) · Alexi_Wright@dfci.harvard.edu · 617-632-2334
Contact: Principal Investigator (Alexi Wright, MD, MPH)
Duke Cancer Center, Durham, North Carolina, United States
Contact: Study coordinator (Amelia Scott) · amelia.lorenzo@duke.edu · 919-613-4584
Contact: Principal Investigator (Laura Havrilesky, MD, MHSc)

Study leads

Alexi A Wright, MD, MPH
Principal Investigator
Dana-Farber Cancer Institute
Joanna J Arch, PhD
Principal Investigator
University of Colorado, Boulder

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Solid Tumor, Adult · Colorectal Cancer · Non Small Cell Lung Cancer

Abroad (travel likely)Recruiting

Gilbert, United States · Phoenix, United States

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

Cancer · Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1

Seoul, South Korea

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

Endometrial Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma

Abroad (travel likely)Recruiting

Buffalo, United States

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer

Abroad (travel likely)RecruitingPHASE2

Hefei, China · Beijing, China